EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Japanese clinical practice patterns of rituximab treatment for minimal change disease in adults 2021: A web-based questionnaire survey of certified nephrologists

Masahiro Koizumi iD, Takuji Ishimoto, Sayaka Shimizu iD, Sho Sasaki iD, Noriaki Kurita iD, Takehiko Wada

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0299053 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Masahiro Koizumi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Kanagawa, Japan. Hauptthemen laut MEDLINE: Nephrologists, Nephrosis, Lipoid. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Ministry of Health, Labour and Welfare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In Japan, rituximab (RTX) for adult-onset frequently relapsing (FR)/steroid-dependent (SD) minimal change disease (MCD) is not explicitly reimbursed by insurance, and its standard regimen has not been established.

Methods

We conducted a cross-sectional web-based survey between November and December 2021. The participants were nephrologists certified by the Japanese Society of Nephrology and answered 7 items about RTX for adult MCD. Factors related to the experience of RTX administration at their facilities were estimated by generalized estimating equations.

Results

Of 380 respondents, 181 (47.6%) reported the experience of RTX use for adult MCD at their current facilities. Those who worked at university hospitals (vs. non-university hospitals, proportion difference 13.7%) and at facilities with frequent kidney biopsies (vs. 0 cases/year, 19.2% for 1–40 cases/year; 37.9% for 41–80 cases/year; 51.9% for ≥ 81 cases/year) used RTX more frequently. Of 181 respondents, 28 (15.5%) answered that there was no insurance coverage for RTX treatment. Of 327 respondents who had the opportunity to treat MCD, which was a possible indication for RTX, 178 (54.4%) indicated withholding of RTX administration. The most common reason was the cost due to lack of insurance coverage (141, 79.2%). Regarding RTX regimens for FR/SD MCD, introduction treatment with a single body surface area-based dose of 375 mg/m 2 and maintenance treatment with a 6-month interval were the most common.

Conclusion

This survey revealed the nephrologists’ characteristics associated with RTX use, the barriers to RTX use, and the variation in the regimens for adult MCD in Japan.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NephrologistsNephrosis, LipoidAdultHumansRituximabJapanPractice Patterns, Physicians'Cross-Sectional StudiesSteroidsSurveys and QuestionnairesInternetTreatment Outcome

Substanzen

RituximabSteroids

Autor:innen und Institutionen

  • Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Kanagawa, Japan.
  • Department of Nephrology and Rheumatology, Aichi Medical University, Aichi, Japan.
  • Section of Clinical Epidemiology, Department of Community Medicine, Kyoto University, Kyoto, Japan.
  • Patient Driven Academic League (PeDAL), Tokyo, Japan.
  • Department of Clinical Epidemiology, Graduate School of Medicine, Fukushima Medical University, Fukushima, Japan.
  • Section of Education for Clinical Research, Kyoto University Hospital, Kyoto, Japan.

ORCID-Profile: Masahiro Koizumi, Sayaka Shimizu, Sho Sasaki, Noriaki Kurita

Förderung

  • Wellcome Trust
  • Ministry of Health, Labour and Welfare

Zitieren

APA

Koizumi, M., Ishimoto, T., Shimizu, S., Sasaki, S., Kurita, N., & Wada, T. (2024). Japanese clinical practice patterns of rituximab treatment for minimal change disease in adults 2021: A web-based questionnaire survey of certified nephrologists. PLOS ONE. https://doi.org/10.1371/journal.pone.0299053

Vancouver

Koizumi M, Ishimoto T, Shimizu S, Sasaki S, Kurita N, Wada T. Japanese clinical practice patterns of rituximab treatment for minimal change disease in adults 2021: A web-based questionnaire survey of certified nephrologists. PLOS ONE. 2024. doi:10.1371/journal.pone.0299053

BibTeX
@article{Koizumi2024,
  author = {Koizumi, Masahiro and Ishimoto, Takuji and Shimizu, Sayaka and Sasaki, Sho and Kurita, Noriaki and Wada, Takehiko},
  title = {Japanese clinical practice patterns of rituximab treatment for minimal change disease in adults 2021: A web-based questionnaire survey of certified nephrologists},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0299053}
}
Kostenlos starten →